- Home
- RDVT vs KMDA Comparison
RDVT vs KMDA Comparison
Compare RDVT & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- KMDA
- Stock Information
- Founded
- RDVT 2017
- KMDA 1990
- Country
- RDVT United States
- KMDA Israel
- Employees
- RDVT N/A
- KMDA N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- RDVT Technology
- KMDA Health Care
- Exchange
- RDVT Nasdaq
- KMDA Nasdaq
- Market Cap
- RDVT 550.8M
- KMDA 442.1M
- IPO Year
- RDVT N/A
- KMDA N/A
- Fundamental
- Price
- RDVT $38.84
- KMDA $7.46
- Analyst Decision
- RDVT Strong Buy
- KMDA Strong Buy
- Analyst Count
- RDVT 1
- KMDA 2
- Target Price
- RDVT $25.00
- KMDA $14.50
- AVG Volume (30 Days)
- RDVT 104.8K
- KMDA 342.2K
- Earning Date
- RDVT 02-27-2025
- KMDA 03-05-2025
- Dividend Yield
- RDVT 0.77%
- KMDA N/A
- EPS Growth
- RDVT N/A
- KMDA 124.29
- EPS
- RDVT 0.36
- KMDA 0.27
- Revenue
- RDVT $70,685,000.00
- KMDA $158,380,000.00
- Revenue This Year
- RDVT $24.88
- KMDA $15.37
- Revenue Next Year
- RDVT $14.52
- KMDA $8.58
- P/E Ratio
- RDVT $109.49
- KMDA $28.13
- Revenue Growth
- RDVT 21.43
- KMDA 4.52
- 52 Week Low
- RDVT $16.56
- KMDA $4.74
- 52 Week High
- RDVT $43.44
- KMDA $9.15
- Technical
- Relative Strength Index (RSI)
- RDVT 50.72
- KMDA 52.89
- Support Level
- RDVT $38.57
- KMDA $7.51
- Resistance Level
- RDVT $41.80
- KMDA $8.35
- Average True Range (ATR)
- RDVT 1.90
- KMDA 0.41
- MACD
- RDVT -0.04
- KMDA -0.02
- Stochastic Oscillator
- RDVT 41.92
- KMDA 33.20
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in big data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses, and assets.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.